PORTLAND, Ore., Dec. 4, 2015 -- A coordinated push to decrypt a complex form of leukemia is delivering a trove of new drug candidates and treatment ideas, a dozen of which will be presented at the American Society of Hematology Annual Meeting in Orlando, Florida (Dec. 5-8).
The research initiative generating these leads, Beat AML, is led by the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society (LLS). Beat AML brings together academic health centers and biopharmaceutical companies to accelerate discoveries that will improve outcomes for patients with acute myeloid leukemia (AML), a blood cancer lacking effective treatments. Less than 25 percent of newly diagnosed patients survive beyond five years.